I. Gunn
1966
Citations
0
Influential Citations
0
Citations
Journal
African Affairs
Abstract
Background. Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activity against nontuberculous mycobacteria, is under clinical development for treatment of MAC lung disease. A population phar- macokinetic (PK) model describing the disposition of EBO after oral (PO) and intra-venous (IV) administration was developed to support EBO PK-PD analyses and dose selection for patients with MAC lung disease. Methods. Model development was conducted using NONMEM (v.7.4.3). Models were attempted for oral absorption, systemic compartments